As of 2026-03-21, the EV/EBITDA ratio of Myriad Genetics Inc (MYGN) is -29.97. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MYGN's latest enterprise value is 398.58 mil USD. MYGN's TTM EBITDA according to its financial statements is -13.30 mil USD. Dividing these 2 quantities gives us the above MYGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.1x - 11.1x | 7.9x |
| Forward P/E multiples | 7.1x - 10.4x | 7.8x |
| Fair Price | (0.70) - (1.16) | (0.80) |
| Upside | -115.2% - -125.3% | -117.4% |
| Date | EV/EBITDA |
| 2026-03-13 | -30.53 |
| 2026-03-12 | -31.87 |
| 2026-03-11 | -33.34 |
| 2026-03-10 | -33.76 |
| 2026-03-09 | -31.59 |
| 2026-03-06 | -33.98 |
| 2026-03-05 | -33.84 |
| 2026-03-04 | -34.89 |
| 2026-03-03 | -34.96 |
| 2026-03-02 | -32.99 |
| 2026-02-27 | -30.18 |
| 2026-02-26 | -31.94 |
| 2026-02-25 | -31.37 |
| 2026-02-24 | -28.91 |
| 2026-02-23 | -28.56 |
| 2026-02-20 | -27.93 |
| 2026-02-19 | -28.56 |
| 2026-02-18 | -28.49 |
| 2026-02-17 | -29.41 |
| 2026-02-13 | -29.34 |
| 2026-02-12 | -29.62 |
| 2026-02-11 | -31.87 |
| 2026-02-10 | -33.48 |
| 2026-02-09 | -33.41 |
| 2026-02-06 | -33.76 |
| 2026-02-05 | -33.62 |
| 2026-02-04 | -35.03 |
| 2026-02-03 | -35.31 |
| 2026-02-02 | -36.23 |
| 2026-01-30 | -37.28 |
| 2026-01-29 | -36.72 |
| 2026-01-28 | -37.98 |
| 2026-01-27 | -39.39 |
| 2026-01-26 | -38.62 |
| 2026-01-23 | -39.04 |
| 2026-01-22 | -40.37 |
| 2026-01-21 | -38.83 |
| 2026-01-20 | -37.70 |
| 2026-01-16 | -39.39 |
| 2026-01-15 | -40.23 |
| 2026-01-14 | -40.73 |
| 2026-01-13 | -41.36 |
| 2026-01-12 | -43.96 |
| 2026-01-09 | -44.03 |
| 2026-01-08 | -43.89 |
| 2026-01-07 | -44.38 |
| 2026-01-06 | -43.61 |
| 2026-01-05 | -40.94 |
| 2026-01-02 | -40.94 |
| 2025-12-31 | -41.01 |